A Multi-centre, Double-blind, Randomised Trial Investigating the Efficacy and Safety of a Combination Therapy, Desmopressin and Tolterodine, for Treatment of Overactive Bladder With Nocturia in Women

Trial Profile

A Multi-centre, Double-blind, Randomised Trial Investigating the Efficacy and Safety of a Combination Therapy, Desmopressin and Tolterodine, for Treatment of Overactive Bladder With Nocturia in Women

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs Desmopressin (Primary) ; Tolterodine (Primary)
  • Indications Nocturia; Overactive bladder
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 09 Oct 2015 Results of post-hoc analysis presented at the 45th Annual Meeting of the International Continence Society
    • 09 Oct 2015 Results presented at the 45th Annual Meeting of the International Continence Society
    • 03 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top